This might indicate novel or unexpected bioactivity that differs from the reference compounds employed in the analysis. In order to analyze and visualize this promising finding, we performed a uniform manifold approximation and projection (UMAP ) analysis with the full morphological profiles (containing 579 features) of these unassigned PNPs and included compounds representing the 13 previously identified bioactivity clusters as markers for the corresponding phenotypic space. The scatter plot shown in figure illustrates that the set of selected subset of 875 cpds for testing in CPA. C: ECDF plot for the normalized spacial score nSPS; for description of datasets, see (A). D: percentage of active (≥ 5% Induction) compounds in the CPA, at 10 and 30 µM for the Enamine-PNP CPA subset. E: Assigned biological clusters for the cpds. active at 10 and 30 µM. F: UMAP plot using the full morphological profiles (579 features) of the 28 (10 µM) / 106 (30 µM) compounds. that were not assigned to any of the 13 clusters; representative compounds for each of the biological clusters have been added as markers for the phenotypic space.